US market architecture for family offices, private-client fiduciaries, and medtech, biotech, and engineering-commercial principals headquartered in Zurich. Swiss discretion is a trust signal at home. It is a category absence abroad.
The Zurich business is real. Standing in the Paradeplatz ecosystem, the Bahnhofstrasse private-banking tier, or the Zurich medtech and biotech cluster has been earned through years of delivery, regulatory cleanliness, and quiet compounding. Revenue is validated. The decision is made to put weight into the US market. A US subsidiary opens, a US acquisition closes, a US co-investment runs, or a portfolio company begins its American commercialisation. The first ninety days do not match the model. US meetings happen. US follow-up goes cold.
The instinct is to stay understated and let the work speak. The instinct is wrong for the American reader. Swiss commercial culture signals seriousness through restraint: precise specification, no oversell, process rigour made visible through what the firm does not claim. US commercial culture reads the same restraint as category absence and hedged conviction. The American buyer does not interpret discretion as depth. They interpret it as uncertainty.
American buyers sort fast on three signals: category anchor, outcome claim, and US peer set. Zurich materials tend to omit the first two by design. The work is to translate the Swiss identity into US-legible visibility without hollowing out what carries at home.
The American buyer is not asking for louder. They are asking for the category, the outcome, and the peer set. Swiss firms omit those three by habit. House view on Zurich to US entry
The rigour is not the problem. The product is not the problem. The American-facing architecture is.
Zurich family-office principals and portfolio holdings with US-facing positioning needs. Holding-brand versus operating-brand architecture, US intermediary-facing trust signals, and US co-investment materials.
Family offices in Zurich →Zurich private-client lawyers, tax advisors, trust officers, and family-office principals introducing international clients to US market engagements. Revenue-neutral, confidential, commission-free.
Fiduciaries in Zurich →The specific shape of the Zurich-to-US register problem. Where Swiss understatement leaves the American reader unable to locate the category, and what the fix looks like.
Swiss discretion vs US visibility →Six to ten weeks. Single US category, single corridor. The firm rebuilds positioning, pricing posture, messaging, and trust architecture for the American buyer, then launches it into market.
See the Sprint →Three to six months. Multi-channel US rebuild and run. Paid, owned, earned, conversion architecture, and sales enablement. The standard shape for Zurich principals committed to US scale.
See the Build →Monthly retainer, twelve-month minimum. Ongoing rebuild-and-run across multiple US surfaces. Typical for Zurich family offices and fiduciary-introduced portfolios with several US-facing brands or holdings.
See the Partnership →No legal services. No Swiss company formation or US entity formation. No FINMA licensing, L-1, E-2, EB-5, or O-1 visa work. No US tax structuring, FATCA analysis, or double-tax-treaty review. No US banking introductions. No fiduciary services. No regulatory licensing. No IP filing. No contract drafting.
These belong with Swiss counsel who specialise in US entry, and with US counsel on the American side. The firm works inside the parameters they set. When a marketing decision carries legal or tax implications, the firm flags it and defers before execution.
Zurich runs on discretion, process rigour, and cantonal-tier reputation. American buyers filter on category anchor, outcome claim, and US peer set before anything else. Swiss understatement that signals seriousness in Paradeplatz reads as hedged or category-unmoored to a US evaluator. The firm does not change at the border. The reader does. The correction is register translation, not identity replacement.
Medtech, biotech, industrials, engineering-commercial firms, and family-office-backed holdings. The firm also works with Zurich-based private-client fiduciaries introducing international principals to US operators. Fit is confirmed in discovery, not in published sector lists.
No. Swiss company formation, FINMA licensing, US LLC or C-corp formation, L-1, E-2, EB-5, and O-1 visa support, transfer pricing, US tax residency, and US banking introductions are handled by the principal's Swiss counsel and US counsel. The firm designs US marketing architecture inside the structure counsel has already put in place.
No. The firm does not pay referral commissions to Zurich lawyers, tax advisors, trust officers, or family offices who introduce principals. Introductions are revenue-neutral. The fiduciary retains the relationship with the principal. The firm delivers the US-facing work inside the structure the fiduciary already manages. Fiduciary introductions route through partnerships@globalmarketing.agency.
With an inquiry through the contact form and a short discovery conversation. The firm runs three engagements: Market Entry Sprint (6 to 10 weeks), Cross-Border Build (3 to 6 months), or Group Partnership (monthly retainer, 12-month minimum). Fit and pricing are confirmed in discovery, not published.
Playbook for Zurich medtech and biotech principals carrying pipeline assets and IP into US commercialisation.
Read the piece →Why Swiss engineering credibility does not translate to US commercial buyers, and what to rebuild first.
Read the piece →The wider DACH gate for operators in Germany, Austria, Switzerland, and Liechtenstein.
See the DACH gate →Non-dom reform rerouting London family-office capital toward Zurich, Dubai, and the US. Cross-hub positioning work.
See London corridor →